Lowell Hart, MD
Medical Oncology · Fort Myers, FLNPI 1245221993
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Lilly USA, LLC at 28.5% of the total. Reporting peaked in 2019 at $159,454 and has fallen 95.0% since, to $8,048 in 2025. Among medical oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,441 payments — averaging $178.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$73K
- Novartis$54K
- Genentech USA, Inc.$23K
- Boehringer Ingelheim$15K
- F. Hoffmann-la Roche AG$15K
- AstraZeneca$14K
- plus $60K from 54 others
Across 517 payments — averaging $19,049 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$7.2M
- Boehringer Ingelheim$1.2M
- Seagen Inc.$413K
- AstraZeneca$294K
- Genentech, Inc.$195K
- Astrazeneca UK Limited$176K
- plus $353K from 14 others
What the payments were for
- Consulting fees$55,99322%
- Speaking & faculty fees$142,08255%
- Travel & lodging$27,11611%
- Food & beverage$30,77612%
- Education$5520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$256,521 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 61 | $1,083,463 |
| IbrancePalbociclib | 49 | $654,721 |
| PomalystPomalidomide | 28 | $599,783 |
| JakafiRuxolitinib Phosphate | 32 | $478,894 |
| TagrissoOsimertinib Mesylate | 27 | $431,769 |
| CalquenceAcalabrutinib Maleate | 40 | $400,018 |
| BrukinsaZanubrutinib | 34 | $287,267 |
| TukysaTucatinib | 11 | $283,348 |
| ImbruvicaIbrutinib | 16 | $255,342 |
| TazverikTazemetostat Hydrobromide | 12 | $244,185 |
| NinlaroIxazomib Citrate | 20 | $194,681 |
| TykerbLapatinib Ditosylate | 12 | $120,234 |
| EliquisApixaban | 82 | $59,697 |
| XareltoRivaroxaban | 39 | $28,616 |
| Exemestane | 41 | $9,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,538 | $1,083,46361 claims |
| AstraZenecaTagrisso, Calquence | $13,936 | $831,78767 claims |
| PfizerIbrance, Eliquis | $2,576 | $714,418131 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,502 | $599,78328 claims |
| Incyte CorporationJakafi | $837 | $478,89432 claims |
| Beigene USA, Inc.Brukinsa | $563 | $287,26734 claims |
| Seagen Inc.Tukysa | $10,549 | $283,34811 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $175 | $255,34216 claims |
| Ipsen Biopharmaceuticals, IncTazverik | $212 | $244,18512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $352 | $194,68120 claims |
| Johnson & JohnsonXarelto | $2,730 | $28,61639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Fort Myers
- Syed ZafarFort Myers$76K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.